Clinical Trial Update: Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sorafenib plus TACE versus sorafenib alone as postoperative adjuvant treatment for resectable primary advanced hepatocellular carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Transarterial chemoembolization (TACE)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: UNKNOWN